Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 6/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9658075 | 0.78 | ARG1 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL17740136 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL978535 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2071540 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL17740138 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL15571615 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2032498 | 0.77 | SLC1A2 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL15904010 | 0.74 | ARG1 (0.44) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL11511876 | 0.70 | SLC1A2 (0.59) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL2806369 | 0.70 | SLC1A2 (0.59) | ARG1SLC1A2MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102414190-B | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2015-06-03 | — | — | CN | disclosed |
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| CN-102414190-A | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2012-04-11 | — | — | CN | disclosed |
| EP-2411376-A1 | INHIBITORS OF NF-KB | Profectus Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010111460-A1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | ARG1 1453/4885SLC1A2 4781/4885MEN1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.